NCT03685578 (EXCELLENT) is a clinical trial of EmboTrap® Revascularization Device in Cerebral Stroke, sponsored by Cerenovus, Part of DePuy Synthes Products, Inc..

Who is sponsoring NCT03685578?

NCT03685578 is sponsored by Cerenovus, Part of DePuy Synthes Products, Inc..

What condition does NCT03685578 study?

NCT03685578 studies Cerebral Stroke.

Is NCT03685578 still recruiting?

NCT03685578 is currently completed. Last updated 3 June 2025.

Last reviewed 2025-06-03 · How we verify

NCT03685578: EXCELLENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CERENOVUS Neurothrombectomy Devices Registry

Completed Last updated 3 June 2025

What this trial tests

trial testing EmboTrap® Revascularization Device in Cerebral Stroke in 2,000 participants. Completed in 20 February 2025.

Timeline

28 September 2018

Primary endpoint
20 February 2025

20 February 2025

Quick facts

Lead sponsor	Cerenovus, Part of DePuy Synthes Products, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	28 September 2018
Primary completion	20 February 2025
Estimated completion	20 February 2025
Sites	40 locations across France, Belgium, United Kingdom, Israel, Germany, Switzerland, United States

Drugs / interventions tested

EmboTrap® Revascularization Device
CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
CEREGLIDE 71 Intermediate Catheter

Conditions studied

Cerebral Stroke — all drugs for Cerebral Stroke →

Sponsor

Cerenovus, Part of DePuy Synthes Products, Inc. — full company profile →

Who can join

18 and older, any sex, with Cerebral Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A post-market registry evaluating the EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC™ Aspiration Catheter, and CEREGLIDE 71 Intermediate Catheter in acute ischemic stroke patients with confirmed intracranial vessel occlusion.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Studying Stroke Thrombus Composition After Thrombectomy: What Can We Learn?
Staessens S, François O, Brinjikji W, Doyle KM, et al · · 2021 · cited 72× · PMID 34517770 · DOI 10.1161/strokeaha.121.034289
EXCELLENT Registry: A Prospective, Multicenter, Global Registry of Endovascular Stroke Treatment With the EMBOTRAP Device.
Nogueira RG, Andersson T, Haussen DC, Yoo AJ, et al · · 2024 · cited 9× · PMID 39559856 · DOI 10.1161/strokeaha.124.047324
Embotrap Extraction & Clot Evaluation & Lesion Evaluation for NeuroThrombectomy (EXCELLENT) Registry design and methods.
Siddiqui AH, Waqas M, Brinjikji W, De Meyer SF, et al · · 2022 · cited 5× · PMID 34645704 · DOI 10.1136/neurintsurg-2021-017671
Quality assessment of histopathological stainings on prolonged formalin fixed thrombus tissues retrieved by mechanical thrombectomy.
Bilgin C, Dai D, Johnson C, Mereuta OM, et al · · 2023 · cited 3× · PMID 38152640 · DOI 10.3389/fneur.2023.1223947
Endotheliitis and cytokine storm as a mechanism of clot formation in COVID-19 ischemic stroke patients: A histopathologic study of retrieved clots.
Brinjikji W, Kallmes DF, Virmani R, de Meyer SF, et al · · 2025 · cited 3× · PMID 37769315 · DOI 10.1177/15910199231185804
Main Abstracts.
· 2021 · cited 1× · PMID 35252582 · DOI 10.1177/23969873211034932
ABSTRACT NUMBER: ESOC2026A2393 THE EXCELLENT REGISTRY (N=2,000): A PROSPECTIVE GLOBAL REGISTRY OF ENDOVASCULAR STROKE TREATMENT WITH CLOT ANALYSIS
· 2026
Abstract 485: Outcomes of Mechanical Thrombectomy in Patients with Pre‐Stroke Disability: Subgroup Analysis from the EXCELLENT Registry
Goyal N, Nogueira R, Siddiqui A, Andersson T, et al · · 2025

Verify or expand the search:

Other recruiting trials for Cerebral Stroke

Currently open trials in the same condition.

NCT06947343 — Effect of Action Observation Therapy in Comparison to Motor Relearning Program on Balance and Mobility Among Subacute St · NA · recruiting
NCT06069999 — Telerehabilitation Early After CNS Injury · NA · active not recruiting
NCT05614193 — Deep Enhanced Imaging in Stroke and Vascular Neurology · recruiting

Other Cerenovus, Part of DePuy Synthes Products, Inc. trials

Trials by the same sponsor.

NCT06386289 — Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke · NA · withdrawn
NCT06735833 — MMA Embolization for Refractory Chronic Migraine · NA · recruiting
NCT04816591 — Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA · NA · completed
NCT04531904 — Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter · completed
NCT03642639 — A Study to Look at Performance of MICRUSFRAME and GALAXY Coils for the Treatment of Intracranial Aneurysms · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03685578 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cerenovus, Part of DePuy Synthes Products, Inc.
Last refreshed: 3 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03685578.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing